Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has a price-to-earnings ratio that is above its average at 55.94x. The stock has a 36-month beta value of 0.28. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NBIX is 96.92M, and at present, short sellers hold a 2.50% of that float. On April 12, 2024, the average trading volume of NBIX was 876.93K shares.
NBIX) stock’s latest price update
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has experienced a decline in its stock price by -1.56 compared to its previous closing price of 138.09. However, the company has seen a fall of -1.22% in its stock price over the last five trading days. Invezz reported 2024-03-28 that “Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024.
NBIX’s Market Performance
Neurocrine Biosciences, Inc. (NBIX) has experienced a -1.22% fall in stock performance for the past week, with a -1.31% drop in the past month, and a 2.67% rise in the past quarter. The volatility ratio for the week is 2.34%, and the volatility levels for the past 30 days are at 3.05% for NBIX. The simple moving average for the last 20 days is -2.67% for NBIX’s stock, with a simple moving average of 14.22% for the last 200 days.
Analysts’ Opinion of NBIX
Many brokerage firms have already submitted their reports for NBIX stocks, with Citigroup repeating the rating for NBIX by listing it as a “Neutral.” The predicted price for NBIX in the upcoming period, according to Citigroup is $127 based on the research report published on December 13, 2023 of the previous year 2023.
Deutsche Bank, on the other hand, stated in their research note that they expect to see NBIX reach a price target of $136. The rating they have provided for NBIX stocks is “Buy” according to the report published on December 12th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to NBIX, setting the target price at $140 in the report published on October 24th of the previous year.
NBIX Trading at -0.89% from the 50-Day Moving Average
After a stumble in the market that brought NBIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.38% of loss for the given period.
Volatility was left at 3.05%, however, over the last 30 days, the volatility rate increased by 2.34%, as shares sank -4.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.32% lower at present.
During the last 5 trading sessions, NBIX fell by -1.22%, which changed the moving average for the period of 200-days by +41.46% in comparison to the 20-day moving average, which settled at $139.36. In addition, Neurocrine Biosciences, Inc. saw 3.16% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NBIX starting from Delaet Ingrid, who sale 272 shares at the price of $137.30 back on Apr 01 ’24. After this action, Delaet Ingrid now owns 7,507 shares of Neurocrine Biosciences, Inc., valued at $37,346 using the latest closing price.
Delaet Ingrid, the Chief Regulatory Officer of Neurocrine Biosciences, Inc., sale 5,000 shares at $145.06 during a trade that took place back on Mar 21 ’24, which means that Delaet Ingrid is holding 7,507 shares at $725,320 based on the most recent closing price.
Stock Fundamentals for NBIX
Current profitability levels for the company are sitting at:
- 0.13 for the present operating margin
- 0.98 for the gross margin
The net margin for Neurocrine Biosciences, Inc. stands at 0.13. The total capital return value is set at 0.1. Equity return is now at value 12.68, with 8.71 for asset returns.
Based on Neurocrine Biosciences, Inc. (NBIX), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at 0.91. The debt to equity ratio resting at 0.19. The interest coverage ratio of the stock is 54.54.
Currently, EBITDA for the company is 416.1 million with net debt to EBITDA at 0.44. When we switch over and look at the enterprise to sales, we see a ratio of 7.26. The receivables turnover for the company is 4.3for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.45.
Conclusion
To sum up, Neurocrine Biosciences, Inc. (NBIX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
